Neurotherapeutic Strategies for Multiple Sclerosis

Teresa C. Frohman, Shin C Beh, Eric J. Kildebeck, Ram Narayan, Katherine Treadaway, Benjamin Greenberg, Elliot Frohman

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

Original languageEnglish (US)
Pages (from-to)483-523
Number of pages41
JournalNeurologic Clinics
Issue number3
StatePublished - Aug 1 2016


  • Adrenocorticotrophic hormone
  • Corticosteroids
  • Disease-modifying therapy
  • Exacerbation
  • MS
  • Multiple sclerosis
  • Pregnancy

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Neurotherapeutic Strategies for Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this